Pfizer obtains rights to Basilea’s Cresemba in Europe

Pfizer has agreed a deal with Basilea Pharmaceutica that will give it exclusive commercialisation rights in Europe to Basilea's drug Cresemba.

This novel antifungal treatment is indicated for adult patients with diagnosed invasive aspergillosis and mucormycosis, two serious infections associated with high morbidity and mortality among immunocompromised patients.

Under the terms of the agreement, Pfizer will be able to distribute and commercialise Cresemba in European territories such as Austria, France, Germany, Italy and the UK, where it is currently available. The Nordic countries are excluded from the scope of the deal.

Pfizer will be responsible for additional Cresemba launches, predominantly in Europe, which are expected throughout 2017 and 2018. Basilea will remain as the marketing authorisation holder for the EU.

Richard Blackburn, global president of Pfizer's Europe, Middle East and Africa business and biosimilars unit, said: "We believe our well-established global presence, together with our deep knowledge of infectious diseases, will enable us to meaningfully address a major unmet medical need."

This follows Pfizer's acquisition of AstraZeneca's small molecule anti-infective business last year and underlines its commitment to this area of medicine.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.